Centogene N.V. Faces Nasdaq Compliance Challenge
Company Announcements

Centogene N.V. Faces Nasdaq Compliance Challenge

Centogene N.V. (CNTG) has released an update.

Centogene N.V., a life science company specializing in rare and neurodegenerative diseases, has been notified by Nasdaq that it is not meeting the minimum bid price requirement after its shares fell below $1 for 30 consecutive days. The company has 180 days to regain compliance with Nasdaq’s minimum bid price rule. In response, Centogene is considering all options to address the deficiency and achieve compliance.

For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCentogene and C-Path Strengthen Drug Development Alliance
TheFlyCentogene & C-Path team on LD research and drug development
GlobeNewswireC-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!